Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Cheryl Galt who wrote (786)	2/26/2000 9:00:00 AM
From: Dr. John M. de Castro	Read Replies (2) \| Respond to of 1494

Thanks Cheryl! I just want to make one clarification. The article states "Unlike some NMDA antagonists that cause significant side effects". This statement could equally apply to NTII's memantine. It also has very few and very mild side effects. In other words, it can do the same thing as the vaccine, do it safely, and, unlike the vaccine, is close to approval for use. Memantine won't be approved for TBI, Stroke, or Epilepsy anytime soon. The company has steadfastly stated that these indications are simply too difficult, risky, and expensive for meaningful clinical trials. The experience of other companies (see CNSI for example) would tend to bear this out. However, I've talked to some of the medical researchers working with memantine and they believe that once it is approved and they are allowed to write scripts, then memantine will get significant "off-label" use for these indications. We shall see how this all plays out. But, it is another very significant market for memantine and memantine is a very significant hope for sufferers from this disorders. Best regards John de C